Skip to main content
Faculty and Staff
Parang  

Keykavous Parang, Pharm. D., Ph.D.

Professor of Medicinal Chemistry
Department of Biomedical and Pharmaceutical Sciences
kparang@uri.edu

Click here for information about Dr. Parang's lab
     

Research Interests

  

Our research is appropriately described as "the application of synthetic organic chemistry to problems in biology". Specific areas currently under investigation include:

  • Designing Protein Kinase Inhibitors Through Target-Based Strategies Using Molecular Modeling, Synthetic and Biochemical Tools.
  • Mechanistic Studies of Protein Tyrosine Kinase Activation by Metals.
  • Novel Strategies in the Solid-Phase Synthesis.
  • Novel Approaches in Designing Bifunctional Antiinfective agents.
     

Education

  

Postdoctoral Fellow, Johns Hopkins University School of Medicine, 2000

Postdoctoral Fellow, Rockefeller University, 1999

Ph.D., University of Alberta, 1997

Pharm.D., University of Tehran, 1989
     
   
     
Selected Publications  

Ye, G., Ayrapetov, M., Nam, N. H., Sun, G., Parang, K. Solid-phase binding assays of peptides using EGFP-Src SH2 domain fusion protein and biotinylated Src. Bioorg. Med. Chem. Lett. (2005) in press.

Parang K., Sun G. Recent advances in the discovery of Src kinases inhibitors. Expert Opin. Ther. Patents (2005) in press. 

Ahmadibeni Y., Parang K. Polymer-bound oxathiaphospholane: A solid-phase reagent for regioselective monothiophosphorylation and monophosphorylation of unprotected nucleosides and carbohydrates. Org. Lett. (2005) 7, 1955-1958.

Ahmadibeni Y., Parang K. Solid-phase reagents for selective monophosphorylation of carbohydrates and nucleosides. J. Org. Chem. (2005) 70, 1100-1103. 

Ayrapetov M. K., Nam N. H., Ye G. Kumar A., Parang K., Sun G. Functional diversity of Csk, Chk, and Src SH2 domains due to a single residue variation. J. Biol. Chem. (2005) 280, 25780-25787.

Carballeira N. M., O’Neill, R., Parang K. Racemic and optically active 2-methoxy-4-oxatetradecanoic acids: Novel synthetic fatty acids with selective antifungal properties. Chem. Phys. Lipids (2005) 136, 47-54. 

Lin, X., Ayrapetov, M. K., Lee, S., Parang, K., Sun, G. Probing the communication between the regulatory and catalytic domains of a protein tyrosine kinase, Csk. Biochemistry (2005) 44, 1561-156.

Parang K., Sun G. Protein kinase inhibitors in drug discovery. Drug Discovery Handbook (2005) Wiley-Interscience, New Jersey, Ed. Gad, S. C. 1191-1257. 

Nam N. H., Ye G., Sun G., Parang K. Conformationally Constrained Tetrapeptide Analogues of pYEEI as Src-SH2 Domain Inhibitors. J. Med. Chem. (2004) 47, 3131-3141.

Nam N. H., Pitts R., Sun G., Sardari S., Tiemo A., Xie M., Yan B., Parang K. Design of Tetrapeptide Ligands as Inhibitors of the Src SH2 Domain. Bioorg. Med. Chem. (2004) 12, 779-787. 

Lee S., LinX., Nam N. H., Parang K., Sun G. Determination of the Substrate-Docking Site of Protein Tyrosine Kinase Csk. Proc. Nat. Acad. Sci. (2003) 100, 14707-14712.

Parang K., Polymer-supported reagents for methylphosphorylation and phosphorylation of Carbohydrates. Bioorganic Med. Chem. Lett. (2002) 12, 1863-1866. 

Parang K., Till J. H., Ablooglu A. J., Kohanski R. A., Hubbard S. R., Cole P. A., Mechanism-based design of a protein kinase inhibitor. Nature Structural Biology (2001) 8, 37-41.

Parang K., Fournier E. J.-L., Hindsgaul O., A solid phase reagent for the capture phosphorylation of carbohydrate and nucleosides. Org. Lett. (2001) 3, 307-309.